Details for Patent: 9,856,211

Title:	Pharmaceutical formulations of HDAC inhibitors
Abstract:	This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxyl-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
Inventor(s):	Bastin; Richard J. (Waterford, IE), Hughes; Nicholas J. (Swindon, GB)
Assignee:	Topotarget UK Limited (GB)
Filing Date:	Aug 05, 2014
Application Number:	14/451,928
Claims:	1. A pharmaceutical composition comprising: (a) a histone deacetylase (HDAC) inhibitor; (b) cyclodextrin; and (c) meglumine: wherein said HDAC inhibitor is selected from compounds of the following formula and pharmaceutically acceptable salts thereof: ##STR00015## wherein: A is a substituted or unsubstituted: C.sub.6-20carboaryl, or C.sub.5-20heteroaryl; Q.sup.1 is: a covalent bond, or a substituted or unsubstituted C.sub.1-7alkylene, C.sub.2-7alkenylene; J is: --NR.sup.N--S(.dbd.O).sub.2--, or --S(.dbd.O).sub.2--NR.sup.N--; R.sup.N is: --H, or a substituted or unsubstituted C.sub.1-7alkyl, C.sub.3-20heterocyclyl, C.sub.6-20carboaryl, C.sub.5-20heteroaryl, C.sub.6-20carboaryl-C.sub.1-7alkyl, or C.sub.5-20heteroaryl-C.sub.1-7alkyl; Q.sup.2 is a substituted or unsubstituted: C.sub.6-20carboarylene, C.sub.5-20heteroarylene, C.sub.6-20carboarylene-C.sub.1-7alkylene, C.sub.5-20heteroarylene-C.sub.2-7alkylene, C.sub.6-20carboarylene-C.sub.2-7alkenylene, C.sub.5-20heteroarylene-C.sub.2-7alkenylene, C.sub.1-7alkylene-C.sub.6-20carboarylene, C.sub.1-7alkylene-C.sub.5-20heteroarylene, C.sub.2-7alkenylene-C.sub.6-20carboarylene, C.sub.2-7alkenylene-C.sub.5-20heteroarylene, C.sub.1-7alkylene-C.sub.6-20carboarylene-C.sub.1-7alkylene, C.sub.1-7alkylene-C.sub.5-20heteroarylene-C.sub.1-7alkylene, C.sub.2-7alkenylene-C.sub.6-20carboarylene-C.sub.1-7alkylene, C.sub.2-7alkenylene-C.sub.5-20heteroarylene-C.sub.1-7alkylene, C.sub.1-7alkylene-C.sub.6-20carboarylene-C.sub.2-7alkenylene, C.sub.1-7alkylene-C.sub.5-20heteroarylene-C.sub.2-7alkenylene, C.sub.2-7alkenylene-C.sub.6-20carboarylene-C.sub.2-7alkenylene, or C.sub.1-7alkenylene-C.sub.5-20heteroarylene-C.sub.2-7alkenylene, and is unsubstituted or substituted. 2. A pharmaceutical composition according to claim 1, wherein the HDAC inhibitor is selected from the following compounds and pharmaceutically acceptable salts thereof: ##STR00016## 3. A pharmaceutical composition according to claim 1, wherein the HDAC inhibitor is selected from the following compound and pharmaceutically acceptable salts thereof: ##STR00017## 4. A pharmaceutical composition according to claim 1, wherein said cyclodextrin is selected from: .alpha.-cyclodextrin; .beta.-cyclodextrin; .gamma.-cyclodextrin; (C1-4alkyl)-.alpha.-cyclodextrin; (C1-4alkyl)-.beta.-cyclodextrin; (C1-4alkyl)-.gamma.-cyclodextrin; (hydroxy-C1-4alkyl)-.alpha.-cyclodextrin; (hydroxy-C1-4alkyl)-.beta.-cyclodextrin; (hydroxy C1 4alkyl)-.gamma.-cyclodextrin; (carboxy-C1-4alkyl)-.alpha.-cyclodextrin; (carboxy-C1-4alkyl)-.beta.-cyclodextrin; (carboxy C1 4alkyl)-.gamma.-cyclodextrin; saccharide ethers of .alpha.-cyclodextrin; saccharide ethers of .beta.-cyclodextrin; saccharide ethers of .gamma.-cyclodextrin; sulfobutyl ethers of .alpha.-cyclodextrin, .beta.-cyclodextrin, and .gamma.-cyclodextrin. 5. A pharmaceutical composition according to claim 1, wherein said cyclodextrin is hydroxypropyl-.beta.-cyclodextrin. 6. A pharmaceutical composition according to claim 1, wherein the molar ratio of cyclodextrin to said HDAC inhibitor is from 0.5 to 5. 7. A pharmaceutical composition according to claim 1, which is a liquid. 8. A pharmaceutical composition according to claim 1, which comprises said HDAC inhibitor at a concentration of 0.1-1000 mg/mL. 9. A pharmaceutical composition according to claim 1, which comprises said HDAC inhibitor at a concentration of 30-300 mg/mL. 10. A pharmaceutical composition according to claim 1, which comprises said HDAC inhibitor at a concentration of 0.3-3000 mM. 11. A pharmaceutical composition according to claim 1, which comprises said HDAC inhibitor at a concentration of 100-500 mM. 12. A pharmaceutical composition according to claim 1, which comprises said HDAC inhibitor at a concentration of 0.01-300 mg/mL. 13. A pharmaceutical composition according to claim 1, which comprises said HDAC inhibitor at a concentration of 1.0-10 mg/mL. 14. A pharmaceutical composition according to claim 1, which comprises said HDAC inhibitor at a concentration of 0.01-100 mM. 15. A pharmaceutical composition according to claim 1, which comprises said HDAC inhibitor at a concentration of 3-30 mM. 16. A pharmaceutical composition according to claim 1, wherein said composition is suitable for parenteral administration to a patient. 17. A pharmaceutical composition according to claim 7, wherein said composition is suitable for administration to a patient by injection or infusion. 18. A pharmaceutical composition according to claim 1, which is a solid. 19. A pharmaceutical composition according to claim 1, which is in the form of a powder, granules, tablets, or a lyophilate/lyophilisate. 20. An intravenous (IV) infusion bag, a vial or an ampoule containing a pharmaceutical composition according to claim 7.